Interleukin-2 gene therapy - Transgene

Drug Profile

Interleukin-2 gene therapy - Transgene

Alternative Names: Ad-IL2; Adeno-IL2; TG 1024; Vero-IL-2

Latest Information Update: 02 Mar 2005

Price : $50

At a glance

  • Originator Transgene
  • Class Gene therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Gastrointestinal cancer; Lung cancer; Mesothelioma

Most Recent Events

  • 23 Feb 2005 Suspended - Phase-I/II for Solid tumours in Switzerland (Injection)
  • 23 Feb 2005 Suspended - Phase-I/II for Renal cancer in Switzerland (Injection)
  • 23 Feb 2005 Suspended - Phase-I/II for Malignant melanoma in Switzerland (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top